Growth-orientated funds could face ongoing pressure in a high-interest-rate environment.
What's good for Wood and Ark Invest might not be good for other investors.
These exciting players could deliver explosive growth over time.
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.
The Ark Invest founder sees potential in these three under-the-radar stocks.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
This gene-editing company could sport a best-in-class platform.
The Ark Invest founder has liked this telehealth stock for several years.
This next-generation gene therapy stock could be a big winner.
This innovator is targeting a huge, rapidly growing market.